Arrowhead (ARWR) Files Form 144 for 611-Share Sale on NASDAQ
Rhea-AI Filing Summary
Form 144 filed for ARWR reports a proposed sale of 611 common shares through Merrill Lynch on the NASDAQ with an aggregate market value of $12,190.05 and 138,257,550 shares outstanding. The notice specifies an approximate sale date of 08/13/2025.
The filing lists the acquisition history for the shares being sold: grants received as compensation on 01/04/2022 (3,485), 01/02/2023 (15,802), 01/04/2023 (12,557), 01/04/2024 (1,167), 01/08/2024 (4,950) and 01/04/2025 (27,271), with the named transferor in those records shown as James Hamilton. The form indicates no securities sold in the past three months and includes the required representation that the seller does not possess undisclosed material information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Small proposed sale disclosed; details show shares were received as compensation over multiple years.
The filing documents a proposed sale of 611 common shares via Merrill Lynch on NASDAQ with an aggregate market value of $12,190.05 and outstanding shares of 138,257,550. The seller's acquisition history is fully listed and characterized as compensation from James Hamilton on specific dates from 2022–2025. The notice also records that no other securities were sold in the prior three months and includes the standard representation regarding material nonpublic information. For investors, this is a routine insider sale disclosure rather than a corporate operational update.
TL;DR: Compliance-focused disclosure showing insider-originated compensation shares and a planned brokered sale.
The Form 144 supplies the regulatory detail necessary for a proposed sale: broker name (Merrill Lynch), exchange (NASDAQ), number of shares (611), aggregate market value ($12,190.05) and the acquisition trail for those shares labeled as compensation with James Hamilton identified as the source across multiple dates. The filing also asserts the signer is unaware of undisclosed material adverse information. This presentation aligns with routine governance and disclosure expectations for executive or insider sales.